Sold as Equagesic. Every FDA application for this active ingredient: 1 branded and 4 generic.
As of Nov 15, 2026, FDA lists 5 applications for Aspirin; Meprobamate (sold as Equagesic), first approved May 27, 1960, with 0 new uses approved and 0 published complete response letters.
| May 27, 1960 | EquagesicNDA 11702 · New combination | Sun Pharm Industries | 17 | Discontinued |
| Jul 31, 1978 | MicraininANDA 84978 | Medpointe Pharm Hlc | 2 | Discontinued |
| Sep 16, 1994 | Mepro-AspirinANDA 89127 | Sandoz | 2 | Discontinued |
| — | Q-GesicANDA 88740 | Quantum Pharmics | 0 | Discontinued |
| — | Meprobamate And AspirinANDA 89126 | Par Pharm | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Sun Pharm Industries
Sandoz
Par Pharm